BeOne Medicines AG
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from BeOne Medicines AG's yearly results (2022–2025), compared with companies in Switzerland. Tap ? on any ratio for what it means.
What stands out
- Tangible Assets Ratio: Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 85% of companies in Switzerland.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-0.1×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Cash Locked Ratio
$16For every $100 of sales, $16 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $8 tied up three years earlier.
Growth quality
Steadiness Ratio
3/3 · 3/3Sales and profit both grew in each of the last 3 years.
Steadier than 80% of companies in Switzerland.
Growth Efficiency Ratio
$58Sales grew 277% in 3 years; of every extra $100 of sales, $58 became extra profit.
Asset Productivity Ratio
+277% / +28%In 3 years sales changed by +277% while total assets changed by +28%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
19.7×Debt due within a year is covered 19.7 times by its yearly operating cash.
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
98%Of every $100 the company owns, $98 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 85% of companies in Switzerland.
Tangible Net Worth Ratio
97%Of every $100 of net worth, $97 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (13)
BeOne Medicines AG owes $0.44 for every $1 it owns. BeOne Medicines AG returned to profit in the year to Dec 2025, after a loss the year before.
Compared with companies in Switzerland · latest annual results Dec 2025.
P/E ratio
68.9Investors pay $68.9 for every $1 of BeOne Medicines AG's yearly profit, higher than 85% of companies in Switzerland.
P/B ratio
8.18The share price is 8.18 times BeOne Medicines AG's book value per share, higher than 75% of companies in Switzerland.
Market cap
HK$332.2 BThe total market value of all of BeOne Medicines AG's shares at today's price (share price × number of shares), larger than 65% of companies in Switzerland. PosiCap size class: Tito Cap.
Net worth (book value)
$5.2 BWhat BeOne Medicines AG would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Return on equity (ROE)
14.7%BeOne Medicines AG earned 14.7% on its shareholders' money over the last year.
Owes vs Owns
0.44×BeOne Medicines AG owes $0.44 for every $1 it owns (low), lower than 75% of companies in Switzerland.
Dividend yield
NoneBeOne Medicines AG does not currently pay a dividend.
Revenue growth
+40%Revenue rose 40% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Profit growth
Back to profitBeOne Medicines AG returned to profit in the year to Dec 2025, after a loss the year before.
Profit margin
5.4%BeOne Medicines AG keeps $5 of every $100 of revenue as net profit.
Cash quality
3.9×Cash from BeOne Medicines AG's business was 3.9× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
7.7×BeOne Medicines AG's operating profit covered its interest costs 7.7 times in the year to Dec 2025.
Cash vs debt
Net cashBeOne Medicines AG held $3.5 B more cash than debt (net cash) at Dec 2025.
Questions
What is BeOne Medicines AG's P/E ratio?
Investors pay $68.9 for every $1 of BeOne Medicines AG's yearly profit, higher than 85% of companies in Switzerland.
What is BeOne Medicines AG's return on equity?
BeOne Medicines AG earned 14.7% on its shareholders' money over the last year.
How much does BeOne Medicines AG owe compared with what it owns?
BeOne Medicines AG owes $0.44 for every $1 it owns (low), lower than 75% of companies in Switzerland.
Does BeOne Medicines AG pay a dividend?
No. BeOne Medicines AG does not currently pay a dividend.
Is BeOne Medicines AG's revenue growing?
Revenue rose 40% in the year to Dec 2025, and grew 56% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.